Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 8Neoplasms 2Recurrence 1Melanoma, Cutaneous Malignant 1Lymphoma 1Locally Advanced Melanoma 1Central Nervous System Neoplasms 1Carcinoma, Merkel Cell 1Carcinoma, Basal Cell 1Brain Neoplasms 1

Interventions

pembrolizumab 9Nivolumab 5aldesleukin 2Specimen Handling 2Magnetic Resonance Spectroscopy 2Ipilimumab 2Interleukin-2 2Cyclophosphamide 2Biopsy 2sargramostim 1relatlimab 1regorafenib 1prednylidene 1lutetium Lu 177 dotatate 1fludarabine phosphate 1fludarabine 1deltacortene 1avelumab 1aflibercept 1X-Rays 1Sirolimus 1Sentinel Lymph Node Biopsy 1Radiotherapy 1Prednisone 1Predictive Learning Models 1Paclitaxel 1Opdualag 1NEO212 1Lidocaine, Prilocaine Drug Combination 1Laparoscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Carcinoma, Merkel Cell × Opdualag × Clear all
NCT06151236 2026-02-17

Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma

Melanoma Institute Australia

Phase 2 Recruiting
20 enrolled
Dermatologic

Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡